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bjectives The aim of this study was to assess the differences in terms of curvature and angulation
f the treated vessel after the deployment of either a metallic stent or a polymeric scaffold device.
ackground Conformability of metallic platform stents (MPS) is the major determinant of geometric
hanges in coronary arteries caused by the stent deployment. It is not known how bioresorbable
olymeric devices perform in this setting.
ethods This retrospective study compares 102 patients who received an MPS (Multi-link Vision or
ience V, Abbott Vascular, Santa Clara, California) in the SPIRIT FIRST and II trials with 89 patients treated
ith the Revision 1.1 everolimus-eluting bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara,
alifornia) from cohort B of the ABSORB (A bioabsorbable everolimus-eluting coronary stent system) trial. All
atients were treated with a single 3  18 mm device. Curvature and angulation were measured with dedi-
ated software by angiography.
esults Both the MPS and BVS groups had signiﬁcant changes in relative region curvature (MPS vs.
VS: 28.7% vs. 7.5%) and angulation (MPS vs. BVS: 25.4% vs. 13.4%) after deployment. The unad-
usted comparisons between the 2 groups showed for BVS a nonsigniﬁcant trend for less change in
egion curvature after deployment (MPS vs. BVS: 0.085 cm1 vs. 0.056 cm1, p  0.06) and a signiﬁ-
antly lower modiﬁcation of angulation (MPS vs. BVS 6.4° vs. 4.3°, p  0.03). By multivariate regres-
ion analysis, the independent predictors of changes in curvature and angulation were the pre-
reatment region curvature, the pre-treatment region angulation, and the used device.
onclusions Bioresorbable vascular scaffolds have better conformability than conventional MPS.
he clinical signiﬁcance of the observed differences will require further investigation. (J Am Coll
ardiol Intv 2010;3:1190–8) © 2010 by the American College of Cardiology Foundation
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1191oronary arteries have variable anatomies that are dynam-
cally changing in morphology through the heart cycle.
cute changes in the geometry of coronary arteries after
mplantation of rigid metallic stents can be related to clinical
utcomes (1). It has been suggested that this interaction can
e explained by the alteration of the flow rheology within
he vessel (2,3) and by the increased risk of stent fracture in
ngulated lesions (4). The most important device property
hat determines these changes in vessel geometry is the
onformability of the stent (5). It is described as the
exibility of a stent in its expanded state with adaptation to
he natural shape of the vessel, hence minimizing trauma to
he vessel wall (6). Stent conformability is dependent on
oth the material and design of the stent and is therefore
ifferent between the commercial devices that are avail-
ble (7,8).
See page 1199
A bioresorbable device capable of providing temporary
caffolding without changing the vessel geometry would be
ighly desirable in order to prevent complications related to the
ermanent presence of metal as stent thrombosis, and proba-
ly, those complications due to changes in vessel curvature such
s restenosis or stent fracture. The everolimus-eluting
ioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa
lara, California) is a new generation of intracoronary devices
hat is currently under investigation in the ongoing ABSORB
A bioabsorbable everolimus-eluting coronary stent system)
rial (9,10). Results so far demonstrate favorable clinical out-
omes out to 3-year follow-up (11); however, the acute effects
f its implantation on vessel geometry are yet to be investi-
ated. Therefore, our aim is to compare the effects of the BVS
n coronary vessel geometry compared with metallic platform
tents (MPS).
ethods
tudy design, population, and treatment device. This non-
andomized, 2-arm, retrospective study has been performed
ith patients from the ABSORB Cohort B trial, and a
ubset of patients from the SPIRIT FIRST (12) and II (13)
rials that received a Multi-link Vision metal platform stent
the bare-metal Vision or the drug-eluting Xience V stent;
bbott Vascular).
All patients in the ABSORB Cohort B trial were treated
ith a device 3.0 mm in diameter and 18 mm in length.
herefore, only those patients enrolled in the SPIRIT
IRST and II trials who received the same stent size were
ligible for this study. The study design of the ABSORB
ohort B is available at the ClinicalTrials.gov website
NCT00856856), whereas the SPIRIT trials have been
ublished elsewhere (12,13). In brief, the common inclusion
riteria were patients 18 years of age or older, with a piagnosis of stable or unstable ischemia and with a de novo
esion in a native coronary artery between 50% and 99%.
xclusions included patients with an evolving myocardial
nfarction, stenosis of an unprotected left main or ostial
ight coronary artery, presence of intracoronary thrombus,
r heavy calcification. Excessive tortuosity proximal to or
ithin the lesion and extreme angulation (90%) proximal
o or within the lesion were also all exclusion criteria.
The ABSORB Cohort B trial included patients treated
ith BVS. The scaffold is a balloon-expandable device,
onsisting of a polymer backbone of poly-L-lactide coated
ith a thin layer of a 1:1 mixture of an amorphous matrix of
oly-D,L-lactide polymer containing 100 g/cm2 of the
ntiproliferative drug everolimus. The implant is radiolu-
ent but has 2 platinum markers at each edge that allow
isualization on angiography and other imaging modalities.
hysically the scaffold has struts with an approximate
hickness of 150 m, which are arranged as in-phase zigzag
oops linked together by 3 longitudinal bridges (Fig. 1).
The SPIRIT FIRST and II trials included patients treated
ith Xience V everolimus-eluting
tent (EES) or Multi-Link Vision
tent (Abbott Vascular). The me-
allic platform is constructed by a
obalt chromium alloy; the EES is
oated by a permanent polymer
nd antiproliferative drug. The
latform consists of serpentine
ings connected by links fabricated
rom a single piece, with a strut
hickness of 81 m. In the EES,
he polymer and drug coating add
combined thickness of 7 m
Fig. 1).
reatment procedure. Lesions were treated with routine
nterventional techniques that included mandatory pre-
ilation with a balloon shorter and 0.5-mm smaller in
iameter than the study device. The BVS was implanted at
pressure not exceeding the rated burst pressure (16 atm).
ost-dilation with a balloon shorter than the implanted
evice was allowed at the discretion of the operator, as was
ailout treatment.
uantitative coronary angiography (QCA) evaluation. The
perator was requested to select an angiographic view with
inimal foreshortening of the lesion and limited overlap
ith other vessels. This view was used for all phases of the
reatment: baseline angiography, pre-dilation, device de-
loyment at maximal pressure, and after devising final result
14). The 2-dimensional (2D) angiograms were analyzed by
he core laboratory (Cardialysis, Rotterdam, the Nether-
ands) with the CASS II analysis system (Pie Medical BV,
aastricht, the Netherlands). In each patient, the treated
egion and the peri-treated regions (defined by 5 mm
Abbreviations
and Acronyms
BVS  bioresorbable
vascular scaffold(s)
EES  everolimus-eluting
stent(s)
MPS  metallic platform
stent(s)
QCA  quantitative coronary
angiography
WSS  wall shear stress
2D  2-dimensionalroximal and distal to the device edge) were analyzed. The
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1192ollowing QCA parameters were measured: computer-
efined minimal luminal diameter, reference diameter ob-
ained by an interpolated method, and percentage diameter
tenosis.
With the same views as the core laboratory, the segment
f interest was defined as the segment between the 2 nearest
ide branches that included the treated region. The proximal
ide branch was used as an index anatomical landmark, and
he distance from this branch to the proximal mark of the
evice in the post-treatment view as well as the device
ength (post-treatment region) was measured. Then, in the
re-treatment view the pre-treatment region (region to be
ubsequently treated) was defined at the same distance from
he referred side branch and from the post-treatment re-
ion (15). The pre-treatment, inflated-balloon, and post-
reatment regions were used to measure the curvature and
ngulation (Fig. 2).
“Curvature” is defined as the infinitesimal rate of change
n the tangent vector at each point of the centerline. This
easurement has a reciprocal relationship to the radius of
he perfect circle defined by the curve at each point. The
urvature value is calculated as 1/radius of the circle in cm1
16), with a research program installed in the QCA Analysis
oftware (CASS II version 1.2 Beta, Pie Medical Imaging).
Figure 1. Structure and Design of Studied Intracoronary Devices
(A) A 1.1 everolimus-eluting bioresorbable vascular scaffold device (BVS) consi
polymer and everolimus. The struts drawn as in-phase zigzag hoops linked tog
and Xience V (Abbott Vascular, Santa Clara, California) are the metal platform
drawn as serpentine rings connected by links fabricated from a single piece. T
thickness is 81 m.his program has been previously described and tested (17). the software automatically detects the lumen contours of
he selected segment and configures the centerline. Three
oints are then defined according to the centerline: 1 at the
roximal, 1 at the distal, and 1 at the center of the defined
egment. Next, a perfect circle is drawn through these
oints, calculating the radius of the circle and the curvature
alue.
“Angulation” is defined as the angle in degrees that the
ip of an intracoronary guidewire would need to reach the
istal part of a coronary bend. Angles were measured with
he modification of a previously described method (18). In
rief, the tangents of the centerlines defined by the 5-mm
roximal and distal parts of the analyzed region at the
nd-diastolic angiographic frame determine the angle (18).
his method was shown to have good interobserver agree-
ent (r  0.94, p  0.01) with a methodological error in
epeated measures of 4.2° (1).
Differences in curvature and angulation were measured in
ystole and diastole separately as values in the pre-treatment
inus values in the post-treatment (Fig. 3). Cyclic changes
n vessel curvature and angulation were estimated as differ-
nces between systole and diastole at pre-treatment and
ifferences at post-treatment.
tatistical analysis. The Kolmogorov-Smirnov test was used
a backbone of poly-L-lactide coated with a thin mixture of poly-D,L-lactide
by 3 longitudinal bridges. The strut thickness is 150 m. (B) Multi-link Vision
and consist of a metallic platform made of cobalt chromium alloy. The struts
nce V is covered by a durable ﬂuorinated polymer and everolimus. The strutsts of
ether
stents
he Xieo evaluate the normality assumptions of all continuous
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1193ariables. Descriptive statistical analysis was performed with
ontinuous variables expressed as median (interquartile
ange) and with categorical variables presented as counts
percentage). For comparison between groups, 2-tailed
tests or Mann-Whitney U test were used for the contin-
ous variables according to the Gaussian distribution. The
hi-square test has been used to assess differences in
ategorical variables. Comparisons within groups have been
stimated with Wilcoxon or Friedman paired tests.
Because the curvature, angulation, cyclic changes of
urvature and angulation, and difference of curvature and
ngulation between pre- and post-treatment did not have a
ormal distribution, a square root transformation was per-
ormed to achieve a normal distribution. A univariate
nalysis was performed between curvature and angulation
hanges with the following variables: age, sex, hypertension,
ypercholesterolemia, diabetes, smoking, previous myocar-
ial infarction, previous coronary revascularization, clinical
resentation, reference vessel diameter, minimal lumen
iameter, diameter stenosis, pre-treatment segment length,
Figure 2. Curvature and Angulation Analysis
Curvature (A) and angulation (B) analysis are shown before deployment (A1 a
(0.203 mm1 in A1 and 0.148 mm1 in A2). Angulation is deﬁned by the tangre-treatment curvature and angle, and cyclic changes in (urvature and angulation. Variables that were found to be
ignificant at the univariate level were tested with a multi-
ariate linear regression model that included the used
evice. The thresholds for entry into and removal from the
odel were 0.1. All statistical tests were carried out at the
% level of significance. All measures were obtained by
PSS version 15 (SPSS, Inc., Chicago Illinois).
esults
tudy population. A flow chart summarizing patient selec-
ion is shown in Figure 4. A total of 191 patients were
ncluded in this study, of which 89 were treated with the
VS and 102 with the MPS (77 patients received Xience V
nd 25 received Multilink-Vision stents). Baseline clinical
ariables are summarized in Table 1. There was no differ-
nce in median age or sex. There were significant differences
n rates of smoking status (16.9% vs. 32.4%, p  0.01) and
trend of higher hypercholesterolemia in the BVS group
) and after deployment (A2 and B2). Curvature is estimated as 1/radius
f the centerlines.nd B183.1% vs. 72.5%, p  0.08).
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1194ngiographic baseline analysis (pre-treatment). The left an-
erior descending artery was the most frequently treated
essel in both groups (44.9% vs. 48.1% in the BVS and
PS, respectively). Quantitative angiographic analysis of
he treated lesion showed significant differences between the
populations in terms of reference vessel diameter (BVS
.57 mm vs. MPS 2.80 mm, p  0.01), minimal lumen
iameter (BVS 1.03 mm vs. MPS 0.99 mm, p  0.03), and
iameter stenosis (BVS 59.0% vs. MPS 63.2%, p  0.02).
here was a trend toward shorter lesion length in the BVS
roup compared with the MPS group (16.3 mm vs. 16.8
m, p  0.06). There were numerically smaller values of
urvature (0.292 cm1 vs. 0.324 cm1, p  0.79) and
ngulation (29.6° vs. 38.1°, p  0.24) in the BVS group
ompared with the MPS group (Table 2).
eometric changes within and between groups. Diastolic
nalysis of the pre-treatment, balloon inflation, and post-
reated regions showed significant differences in curvature
nd angulation between the 3 phases. As expected, the
alloon inflated region had the lowest curvature and angu-
Figure 3. Changes of Curvature and Angulation
(A and B) Case 1 presents a straight vessel, and Case 2 (C and D) presen
(A and C) and post-deployment (B and D) are small in Case 1 (0.010 cm1 anation values (Table 3). mIn both groups, there was a significantly lower curvature
fter treatment than before treatment. The relative median
eduction (i.e., from pre-to post-treatment) in curvature was
.5% in the BVS (from 0.292 to 0.270 cm1, p  0.01),
hereas the corresponding reduction with the MPS was
8.7% (from 0.324 to 0.231 cm1, p  0.01). The nonad-
usted comparison between the 2 devices in terms of change
n curvature showed a nonsignificant trend of less change in
he BVS (p  0.06).
As with curvature analysis, angulation changed signifi-
antly after deployment. The relative median change of
ngulation within pre- and post-treatment measures re-
ulted in less modification with the BVS, 13.4% (from 29.6°
o 25.6°, p  0.01) versus 25.4% with the MPS (from 38.1°
o 28.5°, p  0.01). The nonadjusted comparison between
he 2 devices of change in angulation resulted in signifi-
antly less modification with the BVS (p  0.03).
Cyclic changes (i.e., between systole and diastole) also
howed a significantly lower modification of the hinging
ovements with the BVS than the MPS after the deploy-
urved vessel. Absolute changes in curvature and angulation between pre-
, respectively) and large in Case 2 (0.055 cm1 and 25.7°, respectively).ts a cent in curvature (p  0.01) and angulation (p  0.04).
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1195eometric changes within and between groups in a subset of
atients with more curved and angulated lesions. To evaluate
he changes of curvature and angulation in a subset of patients
ith more curved and angulated vessels, the population was
ivided into 2 halves according the median value of the product
etween curvature and angulation at pre-treatment.
In the group with straight vessels, there were no signifi-
ant changes between the BVS (absolute median change of
.005 cm1 of curvature and 3.2° of angulation) and the
Figure 4. Flow Chart of Patient Selection
BVS  everolimus-eluting bioresorbable vascular scaffold(s); MPS  metal plat
Table 1. Baseline Clinical Variables
BVS (n  89) MPS (n  102) p Value
Age (yrs) 63.0 (55.9–69.3) 62.0 (55.0–71.2) 0.66
Men 65 (73.0%) 70 (68.6%) 0.51
Hypertension 56 (62.9%) 64 (62.7%) 0.56
Hypercholesterolemia 74 (83.1%) 74 (72.5%) 0.08
Diabetes mellitus 15 (16.9%) 16 (15.7%) 0.83
Smoking history 15 (16.9%) 33 (32.4%) 0.01
Previous AMI 23 (25.8%) 28 (27.7%) 0.55
Previous PCI 19 (21.3%) 15 (14.7%) 0.23
Previous CABG 2 (2.2%) 2 (2.0%) 0.89
Clinical presentation 0.75
Stable or silent angina 74 (83.1%) 83 (81.4%)
Unstable angina 15 (16.9%) 19 (18.6%)
AMI  acute myocardial infarction; BVS  everolimus-eluting bioresorbable vascular scaffold;
CABG coronary artery bypass graft; MPSmetal platform stent; PCI percutaneous coronaryintervention.PS (absolute median change of 0.003 cm1 and 6.3°,
espectively) by p  0.73 for curvature, and p  0.18 for
ngulation. In the group with curved and angulated lesions,
here was a significant trend for less modification with the
VS (absolute median change of 0.016 cm1 and 6.3°) than
ith MPS (absolute median change of 0.026 cm1 and
7.3°) by p  0.07 of curvature and p  0.09 of angulation.
tent(s); RCA  right coronary artery.
Table 2. Angiographic Baseline Analysis (Pre-Treatment)
BVS (n  89) MPS (n  102) p Value
Target vessel 0.96
LAD 40 (44.9%) 49 (48.1%)
LCX 20 (22.5%) 29 (28.4%)
RCA 29 (32.6%) 24 (23.5%)
RVD (mm) 2.57 (2.38–2.82) 2.80 (2.54–3.00) 0.01
MLD (mm) 1.03 (0.85–1.24) 0.99 (0.73–1.20) 0.03
Diameter stenosis (%) 59.0 (53.0–66.0) 63.2 (54.4–72.0) 0.02
Pre-treatment region
length (mm)
16.3 (15.0–17.0) 16.8 (16.1–17.3) 0.06
Curvature (cm1) 0.292 (0.179–0.576) 0.324 (0.159–0.571) 0.79
Angulation (°) 29.6 (15.8–55.4) 38.1 (21.1–60.8) 0.24
Cyclic changes in
curvature (cm1)
0.097 (0.035–0.190) 0.091 (0.051–0.173) 0.95
Cyclic changes in
angulation (°)
4.7 (1.9–11.7) 6.4 (2.7–11.4) 0.37
LAD  left anterior descending artery; LCX  left circumflex artery; MLD  minimal lumendiameter; RVD reference vessel diameter; other abbreviations as in Table 1.
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1196redictive factors of modifying curvature and angulation. By
nivariate analysis, the variables related to changes in
urvature were the pre-treatment curvature, cyclic changes
f curvature pre-treatment and device. In the multivariate
odel, the independent predictors of change in curvature
ere the pre-treatment curvature (p  0.01) and the device
sed (p  0.01).
By univariate analysis, the variables related to changes in
ngulation were sex, minimal luminal diameter, diameter
tenosis, pre-treatment angulation, cyclic changes of angu-
ation pre-treatment and device. In the multivariate model,
he independent predictors of change in angulation were the
re-treatment angulation (p  0.01) and the device used
p  0.02).
iscussion
he major findings of the study are: 1) the deployment of
3  18 mm BVS and MPS produces significant
ifferences in vessel geometry in terms of curvature and
ngulation; 2) these changes are significantly less marked
or BVS than for MPS, suggesting better conformability of
he bioresorbable scaffold; and 3) the pre-treatment curva-
ure and angulation and the type of device are independent
redictive factors of vessel changes in curvature and angu-
ation after the deployment.
Our study found that both BVS and MPS modify the
aseline vessel curvature. This change was more accentuated
n patients with more curved and/or angulated vessels at
re-treatment and in patients who received an MPS. Few
tudies have investigated the relationship between changes
n vessel geometry and clinical outcomes after treatment
ith metallic stents. One study found that a pre-treatment
essel angulation more than 33.5° (present in 40.3% of the
atients) and changes in the vessel angulation of more than
.1° (present in 42.6% of the patients) were predictors of
ncreased major adverse cardiac events at 10-month follow-
p. This was largely driven by the increased risk of angio-
Table 3. Geometric Changes Within and Between Groups
Variable Device Pre-Treatment Balloon
Curvature (cm1) BVS 0.292 (0.179–0.576) 0.135 (0.073–0.276)
MPS 0.324 (0.159–0.571) 0.117 (0.051–0.272)
Angulation (°) BVS 29.6 (15.82–55.4) 6.8 (1.8–14.8)
MPS 38.1 (21.1–60.8) 8.2 (2.8–15.9)
Cyclic changes in
curvature (cm1)
BVS 0.097 (0.035–0.190) —
MPS 0.091 (0.051–0.173) —
Cyclic changes in
angulation(°)
BVS 4.7 (1.9–11.7) —
MPS 6.4 (2.7–11.4) —
*Comparisons are made within groups comparing pre- and post-treatment values; †comparison
between groups comparing the mean changes pre–post of each group.
Abbreviations as in Tables 1 and 2.raphic restenosis in these patients treated with a mixture of vrst-generation bare-metal stents (1). In the present study,
he number of patients who had a pre-treatment angulation
33.5° and changes in angulation of 9.1° was 50.3% and
6.6%, respectively.
Nevertheless, some basic science investigations that have
ocused on the change in flow dynamics and wall shear stress
WSS) have reported that curved vessels have a greater
ssociation with turbulent flow and nonuniform distribu-
ions of WSS compared with straight vessels. In addition,
he outer curvature of a coronary vessel is subjected to a
igher WSS, whereas the inner regions have a lower WSS.
n native coronary arteries, regions with low WSS have been
ssociated with a higher frequency of atherosclerotic plaques
19,20). This relationship has also been found between low
SS and the development of thick neointimal hyperplasia
n bare-metal stents (3) and drug-eluting stents (21). It
emains to be investigated whether a fully conformable
evice will have favorable or unfavorable effects on shear
tress.
There is a paucity of data concerning the clinical impli-
ations of changes in vessel geometry with metallic stents.
hus, the clinical benefits associated with better conform-
bility of the BVS require further investigation at medium
nd long-term follow-up and, importantly, should incorpo-
ate assessment of shear stress in the clinical setting.
Moreover, other studies have found a paradoxical re-
ponse to vessel curvature after coronary stenting, with
isplacement of the vessel curvature present before device
mplantation, to the edges of the device after deployment.
hese “inflow” and “outflow” angles might indicate regions
f low WSS (2,22).
The fact that the pre-treatment curvature and angulation
nfluence the changes in vessel geometry is intuitive (a
traight vessel cannot be straightened further) and has been
eported in previous studies (22). The division of our
opulation into 2 halves according to the extent of vessel
urvature and angulation showed that the main changes in
st-Treatment
Relative Changes
Pre vs. Post (%) p Value* p Value† p Value‡
0 (0.114–0.429) 7.5 0.01 0.01 0.06
1 (0.123–0.400) 28.7 0.01 0.01
.6 (12.6–43.1) 13.4 0.01 0.01 0.03
.5 (14.5–45.7) 25.4 0.01 0.01
2 (0.034–0.155) 25.8 0.82 — 0.01
6 (0.023–0.092) 38.5 0.01 —
.6 (2.2–8.7) 1.7 0.01 — 0.04
.8 (1.7–6.3) 41.0 0.01 —
ade within groups comparing pre, balloon, and post-treatment values; ‡comparisons are madePo
0.27
0.23
25
28
0.07
0.05
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3
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1197ending at baseline (Fig. 3). This division has been made
rbitrarily with the median value of the product between
urvature and angulation at pre-treatment, because there is
ot a common consensus defining when a vessel is tortuous,
urved, or angulated.
The relation between baseline coronary bending and
hanges in vessel geometry after device deployment and
linical outcomes cannot only be explained by alteration of
he flow dynamics and WSS within the vessel. Device
mplantation in angulated lesions has been related to metal
tent fracture, which is a well-recognized cause of restenosis
23). The prevalence of metallic stent fracture ranges from
.4% to 29.0% in different registries (24,25). In a study that
ncluded 3,920 patients, a bend of more than 75° was
escribed as an independent predictor of stent fracture (26).
owever, in the context of a polymeric device, by design,
he struts will eventually fracture as a part of the resorption
rocess.
The most important characteristic that will determine
hanges in geometry of the vessel wall is the conformability
f the device, which might be different between currently
ommercially available devices. The device conformability
ill depend on both the design and material of the device
7,8). The comparison of 17 types of bare-metal stents
howed that the material and the design were determinants
n different stent properties, including conformability
22,27). The Xience V stent has been compared with 7
ther different drug-eluting stents in terms of flexibility and
as shown to have a flexibility classified in the mid-range of
he ranking (7). Similar data regarding the BVS are reported
n this study. The materials used by the 2 intravascular
evices in this study are different, and it has an important
ffect on their conformability. In addition, the design
attern is different between the 2 devices (Fig. 1).
tudy limitations. Despite the use of the least foreshortened
iew for the 2D angiographic analysis, it is not the most
ptimal image method to assess the geometry of the
oronary vessels. Three-dimensional assessment has been
roposed as a better alternative to show better correlation
ith the true segment length (28). However, the use of
-dimensional reconstruction from 2D angiograms requires
n accurate acquisition, and despite the use of biplane
mages, sometimes the reconstruction is not possible with
he currently available software (29). In our study, the
easured median device length after the deployment was
6.2 mm for the BVS and 16.6 mm for the MPS, which
epresents an estimated foreshortening of 10.0% and 7.8%,
espectively, according to the real device length (18 mm).
owever, the differences between the pre- and post-
reatment angiographic views were 2°, showing that the
nalysis has been essentially performed in the same angio-
raphic view.
The software used to assess the curvature computed the
enterline according to the luminal contours of the vessel. Inase of eccentric lesions, the centerline was still drawn inside
he lumen, therefore, the curvature might lead to an under-
r overestimation of the real value of the vessel centerline.
he inaccuracy occurring because of this is negligible,
onsidering that we are measuring the difference in curva-
ure and angulation in the same angiographic view during
iastole. Moreover, the measurement at systole and diastole
an be influenced not only by the eccentricity of the culprit
esion, but also by complex coronary shape in the different
oments of the cardiac cycle not detected by the 2D
nalysis.
The presence of calcium might also impact the relation-
hip between vessel geometry and device implantation;
owever, its contribution is poorly defined. We did not
xplore this, because it has been demonstrated that there is
oor correlation between the inter- and intraobserver de-
ection of calcium on coronary angiography (kappa index of
.42 and 0.64, respectively) (30). Multislice computed
omography scanning allows better detection of calcium
ompared with angiography and, moreover, it enables
-dimensional reconstruction of vessel geometry. Analysis
f tissue composition by virtual histology would have been
elpful in interpreting the results; however, virtual histology
as not performed before scaffold implantation and was not
vailable at all in the SPIRIT patients (31).
onclusions
mplantation of a 3  18 mm everolimus-eluting BVS
esults in a significant but modest change in vessel curvature
nd angulation. This change is more accentuated in vessels
ith more severe baseline curvature and angulation. Never-
heless, it is clearly much less extensive than that produced
y conventional metallic platform stents in the acute phase
fter deployment, implying better conformability of the
VS. The clinical significance of the observed differences in
conformability” between bioresorbable and metallic plat-
orm stents is unclear and will require further investigation.
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